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Abstract: Thymic malignancies present particular issues due to the
pace of disease progression, patterns of recurrence, and causes of death
that make nuances of how outcomes are reported particularly important.
The relatively limited number of patients also creates a challenge to
glean as much as possible from the available experience, but risks
over-interpretation and potentially misleading conclusions. Therefore
the International Thymic Malignancy Interest Group has developed a
set of standards for reporting of outcome measures of clinical studies,
which have been adopted for collaborative projects undertaken by the
organization. Widespread adoption of this baseline will enhance the
ability to compare results from different series.
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Thymic malignancies are relatively uncommon, with anincidence of approximately 2.5 to 3.2 per 106 people,1,2 and
care is widely dispersed across many institutions. The literature
consists almost exclusively of retrospective single institution
series, which often extend over multiple decades of experience
to have a reasonable number of patients. Comparing the results
from one center to another is often difficult because of differ-
ences in the outcomes that are reported and the definitions used.
Significant progress cannot be made unless a standard and
uniform set of definitions and outcomes measures are adopted.
The International Thymic Malignancy Interest Group (IT-
MIG) is a collaborative effort of interested individuals around
the world to develop an infrastructure that facilitates progress in
this disease. One of the first steps in this process is the devel-
opment of standard outcome measures and definitions. This
article describes the measures adopted by the ITMIG member-
ship that form the basis for ITMIG collaborative projects.
METHODS
The process used in development of this document was
designed to represent both underlying evidence and a broad
consensus of ITMIG members. An initial workgroup consist-
ing of surgeons, a medical oncologist, and a statistician (J.H.,
F.C.D., P.J.L., and Z.W.) was assembled to review measures
that have been used in the existing literature This workgroup
formulated preliminary recommendations, which were re-
fined by an extended workgroup (Giuseppe Giaccone, Greg-
ory Riely, Nicolas Girard, Meinoshin Okumura, Charles
Thomas, Edith Marom, Andrea Bezjak, and Alexander Brunelli)
and distributed to all ITMIG members for further discussion and
input. The final recommendations, which are presented in this
article, were approved and adopted by ITMIG members at the
annual meeting in New York on May 6, 2010.
PROPOSED MEASURES
Stage Classification
No official stage classification for thymic malignancies
has been defined by the Union Internationale Contre le
Cancer and the American Joint Commission on Cancer.
Various staging systems have been proposed,3 including the
Masaoka system,4 the Koga modification of the Masaoka
system,5 the French Groupe d’E´tude des Tumeurs Thymiques
system,6 and a T, N, and M system.7 Most of centers and
published reports use the Masaoka Stage Classification System,
with studies since 1995 generally using the Koga modification
(Table 1, Masaoka-Koga). The Masaoka-Koga stage classifica-
tion system is recommended by ITMIG for current use.
The Koga modification differs from the original Masaoka
system in that microscopic invasion into (but not through) the
capsule is classified as a stage IIb by Masaoka but as stage I by
Masaoka-Koga. This modification is supported by the fact that
most pathologists do not consider partial invasion into the
capsule to be significant, and survival data appear to bear this
out.5,8,9 Furthermore, this definition of the staging system is
consistent with the definition of encapsulated and invasive thy-
moma adopted by ITMIG (Which way is up? A collaborative
position paper on standards of handling and processing of
thymic tissue by surgeons and pathologists, submitted). Another
*Division of Thoracic Surgery, Department of Surgery, Yale University
School of Medicine and Department of Biostatistics, School of Epide-
miology and Public Health, Yale University, New Haven, Connecticut;
†Thoracic Service, Memorial Sloan-Kettering Cancer Center, New York
City, New York; and ‡HH Gregg Professor of Oncology, Division of
Medical Oncology, Department of Internal Medicine, Indiana University
School of Medicine, Indianapolis, Indiana.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Frank C. Detterbeck, MD, Yale University
School of Medicine, 330 Cedar St. BB 205, New Haven, CT 06520-8062.
E-mail: Frank.detterbeck@yale.edu
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/11/0600-1691
Journal of Thoracic Oncology • Volume 6, Number 7, Supplement 3, July 2011 S1691
difference is that adherence to adjacent structures or microscopic
invasion into but not through the mediastinal pleura or pericar-
dium is classified as stage IIb by Masaoka-Koga but is not
clearly defined in the original Masaoka definition.
Despite widespread use, the Masaoka-Koga system has
many ambiguities that have not been clearly defined. These
issues are beyond the scope of this article and will be
addressed in a separate publication by ITMIG. Furthermore,
evaluation and statistical validation of the stage classification
of thymic malignancies are being undertaken by ITMIG and
the International Staging Committee of the International As-
sociation for the Study of Lung Cancer. This requires collec-
tion of data and details beyond the Masaoka-Koga stage and
will include evaluation of alternative stage classification
schemas. This will be addressed separately in a manual
associated with the ITMIG database.
The focus of staging has been on pathologic stage (i.e.,
as defined after resection). However, the clinical stage (the
assessment before treatment is initiated) is of much more
clinical importance, especially because surgery is not always
the first step in the treatment. Unfortunately, the correlation
of tumor characteristics and the reliability of staging tests in
defining clinical stage have not been well defined. This
subject must be addressed prospectively in a more detailed
manner in a future publication. Until such definitions are
available, we suggest that authors estimate the stage accord-
ing to the Masaoka-Koga system based on their best judg-
ment. We strongly encourage authors to report not only the
pathologic but also the clinical stage.
Survival
A standard outcome measure is overall survival. It is
concrete and generally easy to verify and certainly should be
reported in any clinical outcomes study of thymoma. For many
cancer types, this is an adequate general measure of outcomes
related to the cancer, because survival after a recurrence is
generally short, and the majority of deaths are due to the original
cancer. However, thymomas have a number of characteristics
that make overall survival problematic for assessment of thy-
moma-related outcomes. Many patients die of other causes,
especially in stage I and stage II tumors (Figures 1A, B). Patients
may also live for many years despite a recurrence. There-
fore, more specific measures are needed in addition to
overall survival.
More specific measures generally involve either consid-
ering a specific cause of death or type of recurrence, or both. The
issue of whether the cause of death is determined accurately or
unduly attributed to cancer has been studied in general and
found to be quite reliably assigned,10–12 and it is highly likely to
apply to thymoma as well. However, there are issues with what
is considered a relevant cause of death in the existing literature
on thymoma. Disease-free survival, recurrence-free survival,
cancer-specific survival, progression-free survival, etc., each
involve a different definition of a relevant outcome event as
shown in Table 2. These differences are important in the case of
thymoma, because the incidence of these events is high (Figure
1A). Furthermore, approximately 15 to 20% of patients with
thymoma have or develop another type of cancer as well.3,13,14
As an example, the estimated outcomes for a stage III thymoma
using these different definitions is provided in Figure 2.
Actuarial outcome curves that depict a specific type of
event (e.g., only local recurrence or a particular cause of death)
are often misleading, usually yielding overly optimistic results.15
This is because the actuarial method requires statistical indepen-
dence of the specific event from others, which is generally not
the case (e.g., the time to local recurrence and time to distant
recurrence are likely to be correlated).15 Depending on the
degree to which outcome events are linked, an actuarial estimate
of only one type of outcome (a flawed method) can easily
underestimate the actual rate of this outcome by 30 to 50%.15
Therefore, it is better to analyze death or failure in general, and
then to compare proportional causes of death or failure to avoid
this problem of “competing risks.”15 We propose, therefore, that
TABLE 1. Masaoka-Koga Staging System
Stages Definitions
I Grossly and microscopically completely encapsulated tumor
IIa Microscopic transcapsular invasion
b Macroscopic invasion into thymic or surrounding fatty tissue
or grossly adherent to but not breaking through mediastinal
pleura or pericardium
III Macroscopic invasion into neighboring organ (i.e., pericardium,
great vessel, or lung)
IVa Pleural or pericardial metastases
b Lymphogenous or hematogenous metastasis
Adapted from Pathol Int.5
FIGURE 1. Overall cause (A) and stage-spe-
cific (B) cause of death after resection of pa-
tients with thymoma. Results are an average of
studies from 1980 to 2009 of 100 patients
reporting this data.3
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whenever possible, the proportion of recurrence types and the
proportion of causes of death be reported.
The approach proposed by ITMIG is that assessment of
the efficacy of treatment of a thymic malignancy is best mea-
sured by the rate of recurrence of the thymic malignancy (at any
site). The ability to control related diseases such a Myasthenia
Gravis should be viewed separately. Furthermore, the cause of
death is also a suboptimal measure that is affected by other
factors, and death is best not mixed together with a recurrence
end point. Therefore, we recommend that freedom-from-recur-
rence is the best measure for patients who have successfully
undergone curative-intent treatment (patients with no evidence
of disease, i.e., either an R0 resection or a radiographic complete
response). For patients in whom the disease was never eradi-
cated, time-to-progression is the best measure (Table 3). Time-
to-progression should also be used after an R1 resection, because
residual disease is thought to exist. (The end point of these
measures—recurrent disease—is the same; but the appropriate
term depends semantically on whether disease is still thought to
be still present after treatment or not. Time-to-progression is
chosen for palliative treatments because it is a well-accepted
measure among medical oncologists. Freedom-from-recurrence
is chosen for curatively treated patients rather than time-to-
recurrence because the former emphasizes the likelihood of a
positive outcome, whereas the latter creates the impression that
recurrence is only a matter of time.)
Because of the indolent behavior of thymoma and the
fact that recurrence is associated with a mean survival of
many years, we suggest that for overall survival, 10-year
outcomes should be reported in addition to 5-year outcomes.
For thymic carcinoma, on the other hand, we suggest that
5-year survival is an appropriate measure.
The average time to recurrence of a completely resected
thymoma has been found to be approximately 5 years (range
of reported average, 3–7 years).13,16–21 One study suggested
there was a difference according to stage, observing a mean
time to recurrence of 10 years in patients with a stage I
thymoma, compared with 3 years in patients with a stages II
to IV thymoma.22 (This suggests that more indolent tumors,
with a longer time to recurrence, are more likely to be
detected while they are still stage I.) Given these results, we
suggest that 5-year outcomes are appropriate for freedom-
from-recurrence studies in general, although it is probably
better to have 5- and 10-year results for stage I tumors.
A concept that is often forgotten is that actuarial survival
curves (e.g., Kaplan-Meier) provide an estimate of survival
FIGURE 2. Specific outcomes for a stage III resected thy-
moma at 10 years, estimated from data regarding overall
survival, cause of death, incidence of recurrence, and inci-
dence of other cancers.3
TABLE 2. Survival Measures
Measures Events (End Point of Interest) Censored Observationsa Included Patients
Overall survival Death, any cause Allb
Disease-related survival Death from TM, MG,c Treatment Unrelated death,d unknown cause of death Allb
Disease-specific survival Death from TM, MGc Unrelated death,d unknown cause of death Allb
Cause-specific survival Death from TM Unrelated death,d unknown cause of death Allb
Cancer-specific survival Death from any Cancer Unrelated death,d unknown cause of death Allb
Disease-free survivale Death, recurrence Unknown recurrence status R0/CR
Freedom from recurrence Recurrence Dead without recurrence; Unknown recurrence status R0/CR
Progression-free survival Death, progression of TM Unknown status of TM R1,2/PR, SD
Time-to-progression Progression of TM Dead without progression, Unknown status of TM R1,2/PR, SD
a In all categories includes patients lost to follow-up or without an event at termination of study period.
b Either all patients or may be restricted to a specific group (e.g., R0 resected patients only).
c Or other thymoma-related disease (e.g., red cell dyscrasia and hypogammaglobunlinemia).
d Definition of related determined by the definition of an event.
e Disease-free survival usually means the same as recurrence-free survival but sometimes may include MG as an event.
CR, complete radiographic response (no residual tumor identified); MG, myasthenia gravis; PR, partial response; SD, stable disease (after treatment with chemoradiotherapy or
radiotherapy); TM, thymic malignancy.
TABLE 3. Recommended Outcome Measures
Measures Patient Cohort Starting Point
Overall survival For all patients Date of diagnosis
Freedom-from-
recurrence
For patients after successful
curative treatment (R0
resection or radiographic
CR after chemotherapy or
radiotherapy)
Completion of
treatment
Time-to-
progression
For treated patients in whom
all disease was not
eradicated (R1,2 resection,
radiographic SD, or PR)
Completion of
treatment
CR, complete response, PR, partial response, SD, stable disease.
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(because some patients have been lost or have not been followed
up for the entire duration of the study). The variance of this
estimate is dependent on the sample size, the duration of follow-
up, the study duration, and the median survival. The variance is
fairly wide for cohorts of less than approximately 50 patients,
and this is accentuated in studies of shorter duration (Figure 3A,
B). In a rare disease, large patient cohorts are often simply not
available; however, it is important to have an assessment of the
limitations of the available data. Therefore, we recommend that
the confidence interval for a survival estimate should be pro-
vided. We also propose that the median follow-up be reported in
all studies (duration from time of patient entry into the study
until the event of interest, termination of the study, or loss to
further follow-up, as a median for the entire study cohort).
Completeness of Surgical Resection
The completeness of resection has frequently been iden-
tified by multivariate analysis as a major prognostic factor.3,23
However, details of how specimens are handled and how mar-
gins are reported vary among studies. Because of the nature of
the anatomy and the often loose areolar tissue surrounding the
thymus, there is potential for significant misclassification (IT-
MIG. Which way is up? A collaborative position paper on
standards of handling and processing of thymic tissue by sur-
geons and pathologists, submitted). ITMIG has proposed stan-
dards for handling, processing, and reporting of pathologic
results of resected thymic tumors to minimize this (ITMIG.
Which way is up? A collaborative position paper on standards of
handling and processing of thymic tissue by surgeons and
pathologists, submitted). In brief, areas of concern should be
marked immediately during dissection in a way that minimizes
disruption of the overlying tissues and provides clear orientation
and communication between the surgeon and pathologist. The
pathology staff should take care in the gross preparation of the
sample to section in a way that allows definition of these areas.
A positive margin denotes tumor extending to an inked surface
of the specimen that involves tissues that have been cut or
dissected. Exposed tumor on a mediastinal pleural or pericardial
surface, which is bounded by the space of a normal body cavity
(i.e., no adhesions present), does not constitute a positive mar-
gin. One of the difficulties in thymoma resection is that the loose
areolar tissues surrounding the thymus can easily be disrupted
during handling, resulting in exposed tumor in the specimen that
was in fact not due to dissection on the surface of the tumor
(ITMIG. Which way is up? A collaborative position paper on
standards of handling and processing of thymic tissue by sur-
geons and pathologists, submitted). Such areas should not be
counted as a positive margin, provided the area has been clearly
identified as not having been grossly concerning in situ and
having been disrupted during handling, as outlined in a separate
publication (ITMIG. Which way is up? A collaborative position
paper on standards of handling and processing of thymic tissue
by surgeons and pathologists, submitted).
Definition of Recurrence
The term recurrence is appropriate if it is thought that
all disease has been potentially eradicated (an R0 resection or
a complete radiographic response has been achieved). We
propose that a recurrence be defined to have occurred when
there is a strong clinical suspicion (or proof), without a
specific requirement of what tests (i.e., imaging and biopsy)
this is based on. Given that the survival with disease can
sometimes justify observation alone, requiring tissue confirma-
tion or a decision to treat will underestimate recurrence. The
time of the recurrence should be recorded as the time when a
strong suspicion first existed, even if subsequent events (i.e.,
radiographic progression or biopsy) make the clinical diagnosis
even more secure at a later time. When significant doubt exists,
a biopsy is encouraged whenever feasible.
Rarely, there may be a strong suspicion that is later
conclusively shown to have been in error (i.e., biopsy or
spontaneous regression). In such cases, the diagnosis of
recurrence should be (retroactively) rescinded. However, the
onset of a recurrence should not be retroactively assigned,
meaning that one should not reassign the onset of recurrence
to a time before there was any clinical suspicion, even if a
FIGURE 3. Variance in actuarial survival estimates by size of cohort for (A) a 10-year study duration and (B) a 5-year study
duration. The vertical bars are 95% confidence intervals for the survival estimate at 5 and 10 years, based on a standard
model of exponentially decreasing survival, a constant rate of accrual of patients during the course of the study until study
termination, and no loss to follow-up. MST, median survival time.
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retrospective review of imaging demonstrates an abnormality
that was missed but was later found to be a recurrence.
The frequency of follow-up imaging may affect when a
recurrence is first suspected. We suggest that at a minimum,
yearly computed tomography (CT) scans of the thorax be per-
formed for 5 years after surgical resection and then alternating
annually with a chest radiograph until year 11, followed by
annual chest radiographs alone. Resected stage III or IVa thy-
moma, thymic carcinoma, incomplete resection, or other high-
risk tumors are suggested to undergo additional CT imaging
every 6 months for 3 years. Obtaining a new “baseline” exam-
ination after resection when acute inflammatory effects have
resolved (i.e., 4–12 weeks postoperatively) may be very useful
for comparison. Magnetic resonance imaging may be useful
instead of CT either for better visualization or to minimize
cumulative radiation dose (especially in young patients). Posi-
tron emission tomography (PET) imaging is not recommended
for routine surveillance but, if available, may selectively be of
benefit (e.g., to investigate a clinical or radiographic suspicion of
recurrence). A more frequent follow-up schedule has been pro-
posed21 (annual CT for life), but this may be less broadly
applicable in the disparate health care systems around the world.
A local recurrence should be defined as disease appear-
ing in the bed of the thymus (i.e., the anterior mediastinum)
or tissues immediately contiguous with the normal thymus or
with the thymoma (Table 4). This should include involve-
ment of lymph nodes or pleural or pericardial tumor that is
immediately adjacent to the previous primary tumor. Simi-
larly, a recurrence in the exact area of a previously resected
noncontiguous pleural metastasis (stage IVa) should be clas-
sified as a local recurrence, with the additional notation of
“recurrence of a noncontiguous metastasis.” Finally, disease
in the lower neck contiguous with the location of the upper
poles of the thymus should be classified as local recurrence.
A regional recurrence should be defined as intrathoracic
tumor that is not immediately contiguous with the thymus gland
or the previous thymic neoplasm. This would include pleural
(parietal or visceral) and pericardial nodules as noted in Table 4,
unless these are in the bed of the previously treated tumor. A
nodule that is contiguous with the pleura (including the fissures)
is designated as a visceral pleural nodule. A regional recurrence
also includes lymph nodes that are not adjacent to the thymus or
the thymic tumor (e.g., periesophageal or more distant neck
nodes).
A distant recurrence includes disease outside the thorax or
the lower neck. Disease in the peritoneal cavity or retroperito-
neum should be classified as distant unless it is arising from local
extension through the diaphragm of an intrathoracic nodule(s).
We propose that the term distant recurrence also in-
clude nodules that are clearly intrapulmonary, with a clini-
cally visible rim of lung tissue between it and the visceral
pleura (either radiographically or on gross examination). This
is based on speculation that the mechanism of spread of a
nodule under the visceral pleura is through the pleural space
and that of an intraparenchymal pulmonary nodule is
through the bloodstream. However, there are no data to
substantiate this speculation and no data defining the
clinical impact of making this distinction. To prospectively
study this, a distant recurrence consisting only of an
intraparenchymal nodule should be recorded separately
from other extrathoracic recurrences.
Response to Chemotherapy and Radiation
Chemotherapy and radiation are often used as induction
therapy before resection, as definitive therapy with curative
intent for inoperable disease, or for palliation. The standard way
to assess a patient’s response to therapy is unidimensional tumor
measurement by CT according to the RECIST criteria (version
1.1)24 Although these criteria may be suitable for most solid
tumors in general, the anatomic aspects of thymic malignancies,
with their large size, location, irregular shape, and intimate
relationship with neighboring structures make it particularly
difficult to attain consistent measurements. Measurements using
either hand-held or electronic calipers have high intra- and
interobserver variability, particularly for tumors with irregular or
vague borders.25,26 Therefore, we recommend that tumor re-
sponse assessment be performed by one person, ideally a radi-
ologist experienced with tumor measurements.25
Thymic malignancies may also respond by undergoing
cystic change, central necrosis, and density changes that may
not be captured by conventional measurements of the largest
lesion diameter. Another issue is that in lymphocyte-rich
thymomas, a significant response can be seen simply by the
effect of chemotherapy (or even prednisone) on the normal
lymphocytes and not the tumor cells. Other complicating
factors include the predilection of thymic malignancies for
pleural involvement, which poses a significant challenge for
administering standard RECIST methods. Although the stan-
dard RECIST criteria exclude pleural nodules, because of
their importance in thymoma, these should be measured and
included, similar to mesothelioma.27 Tumor volume measure-
ments may enable more objective, accurate, and consistent
assessment of therapy response than the traditional unidimen-
TABLE 4. Definitions of Recurrence (After R0 Resection or
Radiographic Complete Response)
Local recurrence—anterior mediastinum
Tumor occurring in bed of thymus or previously resected thymoma
Includes pericardial, pleural, or pulmonary tumor that is immediately
adjacent to the thymus or previously resected thymoma
Lymph nodes immediately adjacent to the thymus or previously
resected thymoma (including nodes in the neck immediately adjacent
to the upper poles of the thymus)
Recurrence at the site of a previous noncontiguous metastasis (stage
IVa)—should be specifically noted as such
Regional recurrence—intrathoracic recurrence not contiguous with thymus
or previous thymoma
Parietal pleural nodules
Pericardial nodules
Visceral pleural nodules
Mediastinal lymph nodes not adjacent to the normal thymus or the
previous thymic malignancy
Distant recurrence
Extrathoracic recurrence
Intraparenchymal pulmonary nodules (with rim of normal lung between
the nodule and the visceral pleura)
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sional technique. These approaches require further investiga-
tion and validation and are currently being studied.
In the interim, conscientious adherence to standard revised
RECIST criteria (version 1.1) for response assessment is recom-
mended.24 All measurable lesions up to a maximum of two
lesions per organ and five lesions in total, representative of all
involved organs, should be identified as target lesions and
recorded and measured at baseline. Target lesions should be
selected on the basis of their size (i.e., the longest diameter [LD])
and their suitability for accurate repeated measurements (either
by imaging techniques or clinically). A sum of the longest (or
most accurately determined diameters) for all target lesions is
calculated and serves as the reference by which objective tumor
response is assessed.28
An exception to this rule is pleural lesions, as the tumor
thickness is more clearly and consistently measured than the
long axis spread along the lining of the chest wall or the
mediastinum.27 For extensive pleural involvement, the tumor
thickness perpendicular to the chest wall or mediastinum is
measured in two positions at three separate levels on thoracic CT
scans.27 The sum of the six measurements defines a pleural
unidimensional measure. The sum of the pleural unidimensional
measure with the sum of the LD (or the most accurately
determined diameter) for all non-pleural target lesions up to a
total of five defines the baseline sum LD, against which subse-
quent tumor response or progression is compared.24,27
Disease progression should be defined according to the
revised RECIST criteria (version 1.1).24 The timing of rec-
ognition of progression is, of course, potentially also influ-
enced by the frequency of assessment. We propose that for
resected stage III or IVa thymoma, thymic carcinoma, incom-
plete resection, or other high risk tumors undergo imaging at
least every 6 months for 3 years.21 Earlier stage tumors
should follow annual imaging as outlined earlier in the
Definition of Recurrence section.
Evidence of treatment effect can also be assessed by
histologic evaluation of tumor tissue after chemotherapy or
radiotherapy. Inflammation, necrosis, and fibrosis are often
seen admixed with viable tumor, and the degree of treatment
effect can be visually quantified as a percentage of viable
tumor in increments of 10%. A pathologic complete response
exists when no viable tumor is identified throughout the entire
specimen. The number of sections examined to determine this is
important. At least one section for every centimeter of tumor
diameter is recommended (ITMIG. Which way is up? A collab-
orative position paper on standards of handling and processing
of thymic tissue by surgeons and pathologists, submitted).
Multivariate Analysis
The availability of statistical software has made it much
easier to perform multivariate analyses to identify potential
prognostic factors. However, the statistical science is often not
well understood by the authors, and conclusions are often over-
stated. Essentially, all prognostic factor studies in thymic malig-
nancies to date have been exploratory, so-called phase I prog-
nostic factor studies. There is nothing wrong with such
exploration, but external validation is essential.29 There are
many potential sources of bias. For example, when using step-
wise regression analysis, different predictive factors may
emerge, depending on whether a forward model or backward
model is used and depending on the order in which variables are
introduced. The regression coefficients in the final model are
generally overestimated, thus the p value in these analyses is not
actually valid (because the same data used to define the variable
is used to estimate the prognostic effect).29 The same applies to
survival curves with and without the prognostic factor that have
not adjusted for other factors. Furthermore, when a cutoff value
is chosen to dichotomize a continuous variable based on the best
discriminatory power, the chance of a false-positive prognostic
factor is about 40%, despite a p value of0.05.30 The technique
of bootstrapping can overcome some of these difficulties.31
There is also a high chance of false-negative results when
investigating potential prognostic factors, mainly because of
insufficient sample size. It is easy to see how a conclusion can be
reached that a factor has no independent prognostic significance,
when in reality the sample size was too small to detect a
difference (for a given effect size). A general estimate of the
minimum sample size needed can be calculated using an online
tool for multiple regression analysis, with results shown in Table
532 This must be viewed as only a rough estimate, because other
characteristics of the cohort (e.g., uneven distribution of a
potential prognostic factor) also play a role. A more detailed
analysis requires the involvement of a statistician.
Because sample size is a major issue in a rare disease,
such as thymoma, performing and interpreting the results of
a multivariate analysis must be done with caution. We rec-
ommend that multivariate studies of prognostic factors in-
volve the help of a statistician. The study should include
definition of the parameters chosen for the analysis (i.e., level
of significance and power). Furthermore, the results should be
stated in a way that represents an accurate perspective (e.g.,
“this study suggests that several factors are not likely to have
a large prognostic effect, although the sample size is insuf-
ficient to evaluate a small or medium-sized effect” or perhaps
“the factors did not appear to have prognostic significance,
but the power of detection of even a large effect in this
TABLE 5. Sample Size Needed for Multiple Regression
Analysis
No. of
Predictors
to be Tested
Power  0.80
Effect Sizea
Power  0.60
Effect Sizea
Small Medium Large Small Medium Large
2 478 67 31 308 44 21
3 543 76 36 356 52 25
4 597 84 39 395 58 28
5 643 91 43 429 63 31
6 684 97 46 460 68 33
7 721 103 49 488 72 36
8 755 108 52 513 76 38
9 788 113 54 538 80 40
10 818 118 57 561 84 42
Estimate of minimum sample size needed to assess a given number of potential
predictors, assuming a level of significance of p  0.05.
Values calculated using an online tool available at: http://www.danielsoper.com/
statkb/topic01.aspx.32
a Effect size using conventional levels of (f2) of 0.02, 0.15, and 0.35 for small,
medium, and large effects, respectively.
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limited study was only 0.40”). Ideally, the hazard ratio of
each variable should be reported together with 95% confi-
dence intervals. However, in most cases, the findings must be
externally validated before drawing any serious conclusions.
DISCUSSION
A common language is essential to sharing experiences
across different centers, and because thymic malignancies are
uncommon, such collaboration is crucial. ITMIG is an organi-
zation of individuals interested in this disease and is devoted to
providing infrastructure and processes that foster collective re-
search. This article establishes a baseline for ITMIG regarding
how outcomes should be reported. Details of how endpoints are
defined are clarified, to avoid the ambiguity and inability to
combine data that have persisted in the past because of a lack of
uniformity. These definitions will be used in ITMIG collabora-
tive projects. We also hope that this will be a useful guide in
general for studies of thymic malignancies.
We have also included basic facts regarding the statis-
tics of clinical outcomes as they apply to a relatively uncom-
mon and often indolent disease such as thymoma. There are
limitations to the strength of conclusions that can be drawn
from studies involving a modest number of patients. Pointing
this out is not meant to discourage analysis of the experience
in individual centers, which will often suffer from a limited
number of patients. Instead, it is meant to help the general
medical community remain realistic about the strength of the
data that we have. There is nothing wrong with trying to
glean as much knowledge as possible from the experience we
have, but there are potential issues if we overstep what can be
concluded without realizing it.
Any “standard” must be viewed as merely a baseline in
a fluid process. We hope this article will encourage all who
are reporting on thymic malignancies to use the proposed
definitions and hope it will stimulate a careful appraisal of the
weaknesses and of unproven measures. Furthermore, we hope
this article will inspire an exploration of new measures. We
fully anticipate subsequent formal changes to occur to at least
some of the proposed measures once a good scientific basis or
at least a solid consensus has been established.
In summary, this article establishes outcome measures
and definitions appropriate for thymic malignancies. This
represents a consistent baseline agreed on by ITMIG that will
be used in ITMIG collaborative projects, and we hope it will
be a useful guide for the medical community in general.
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